Charlie Abrahams, Senior Vice President, MarkMonitor
Want brand protection that counts toward your bottom line?
Start with your consumer. Research shows that 23 percent of shoppers unknowingly purchase counterfeits.
In this webinar, we hear how the right technology and best practices can ensure that the most visible pages in search listings, marketplaces and paid search ads are as clean as possible from counterfeit, pirated and grey market listings.
The UK Supreme Court's 2017 decision in Actavis v Eli Lilly introduced a doctrine of equivalents into UK law. In this webinar, we'll discuss the implications of that decision and look at how it is being applied in other cases in the UK courts.
Personalised healthcare (sometimes referred to as precision medicine) is an evolving field in medicine where a therapeutic treatment is tailored to an individual with a particular disease. The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, most notably the USA. However, various aspects of these inventions are patentable in Europe.
This webinar will set the scene as to what personalised healthcare is and will run through the history of second medical use patenting in Europe. Discussing key cases such as G5/83, T1020/03 and G2/08.
It will then focus on how second medical use patenting can be applied to personalised healthcare inventions and will give examples of claim language that is finding favour at the EPO.
This webinar will be on opposition and appeals practice before the EPO. We’ll be discussing the streamlining of the opposition procedure by the EPO, the changes that we are seeing as a result and will be providing practical tips in view of these changes. The talk will also draw on recent case law.
Over the last 10 years, multiple patents on therapeutic antibodies have been invalidated in the courts, often for lack of written description. Many other cases are working their way through the courts and the PTAB. This webinar will review major CAFC and PTAB decisions affecting therapeutic antibodies and will explore the best ways to obtain valuable and enforceable patents on therapeutic antibodies. The main issues to be covered are Section 101 issues (laws of nature, natural phenomena and natural products), obviousness and written description.
With the year approaching its end, many IP departments will be looking at how best to rationalise their work for 2018. This webinar explores how to ensure your trademark portfolio is in the best possible shape using a two part verification and audit process to save you time and money on your IP assets, as well as analyzing your current and planned costs and guiding your filing strategy in the new year.
Join WIPR and RWS IP Services for a complimentary webinar as we discuss patent filing strategies in China.
As the largest growing consumer market in the world, enforcing your intellectual property (IP) in China has become increasingly critical. In this webinar, we will discuss the ten steps your organization should take when seeking patent protection and help you formulate your commercial IP strategy.
This webinar will cover the current state of play in Europe regarding biotech patentability issues, including recent case law on what data you need to make an invention in this area plausible. It will also look at how recent rule changes have influenced patentability of plants and animals before the EPO. Finally, we will compare patentability practice in different jurisdictions around the world, most notably in the US, China and Japan.
The CRISPR IP landscape in Europe is very murky. Listeners will gain an understanding of the current situation, which will aid them to make licensing decisions if and when they intend to commercialise. This 45-minute webinar will provide an up to date analysis of the current state of play in Europe with comparison to the state of play in the US.